TY - JOUR AU - Shaib, Walid AU - Mahajan, Reena AU - El-Rayes, Bassel PY - 2013 TI - Markers of resistance to anti-EGFR therapy in colorectal cancer JF - Journal of Gastrointestinal Oncology; Vol 4, No 3 (September 11, 2013): Journal of Gastrointestinal Oncology Y2 - 2013 KW - N2 - Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways. UR - https://jgo.amegroups.org/article/view/1154